Supercharged immune cells take on deadly brain tumors
NCT ID NCT07579208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new approach for people with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. Researchers will give patients specially engineered natural killer (NK) cells, either directly into the brain or through an IV, to see which method is safer. The study involves 36 adults and focuses on side effects and the best way to deliver the cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered natural killer (NK) cells
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few options.
What could go wrong
This is a very early Phase 1 trial with only 36 people. It is designed mainly to check safety, not yet to prove the treatment works. There may be side effects from the cells or the delivery method.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact